BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002;16:1713-1724. [PMID: 12200686 DOI: 10.1038/sj.leu.2402608] [Cited by in Crossref: 288] [Cited by in F6Publishing: 301] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Miari KE, Williams MTS. Stromal bone marrow fibroblasts and mesenchymal stem cells support acute myeloid leukaemia cells and promote therapy resistance. Br J Pharmacol 2023. [PMID: 36609915 DOI: 10.1111/bph.16028] [Reference Citation Analysis]
2 Bouligny IM, Maher KR, Grant S. Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. Blood Rev 2023;57:100996. [PMID: 35989139 DOI: 10.1016/j.blre.2022.100996] [Reference Citation Analysis]
3 Skelding KA, Barry DL, Theron DZ, Lincz LF. Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia. Int J Mol Sci 2022;24. [PMID: 36614005 DOI: 10.3390/ijms24010563] [Reference Citation Analysis]
4 Yüce M, Albayrak E. Hyperthermia-stimulated tonsil-mesenchymal stromal cells suppress hematological cancer cells through downregulation of IL-6. J Cell Biochem 2022;123:1966-79. [PMID: 36029519 DOI: 10.1002/jcb.30322] [Reference Citation Analysis]
5 Le BV, Podszywałow-Bartnicka P, Piwocka K, Skorski T. Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. Cancers (Basel) 2022;14. [PMID: 36497275 DOI: 10.3390/cancers14235795] [Reference Citation Analysis]
6 Nachmias B, Zimran E, Avni B. Mesenchymal stroma/stem cells: Haematologists' friend or foe? Br J Haematol 2022;199:175-89. [PMID: 35667616 DOI: 10.1111/bjh.18292] [Reference Citation Analysis]
7 Luciano M, Krenn PW, Horejs-hoeck J. The cytokine network in acute myeloid leukemia. Front Immunol 2022;13:1000996. [DOI: 10.3389/fimmu.2022.1000996] [Reference Citation Analysis]
8 Ramuta TŽ, Kreft ME. Mesenchymal Stem/Stromal Cells May Decrease Success of Cancer Treatment by Inducing Resistance to Chemotherapy in Cancer Cells. Cancers 2022;14:3761. [DOI: 10.3390/cancers14153761] [Reference Citation Analysis]
9 Hino C, Pham B, Park D, Yang C, Nguyen MH, Kaur S, Reeves ME, Xu Y, Nishino K, Pu L, Kwon SM, Zhong JF, Zhang KK, Xie L, Chong EG, Chen C, Nguyen V, Castillo DR, Cao H. Targeting the Tumor Microenvironment in Acute Myeloid Leukemia: The Future of Immunotherapy and Natural Products. Biomedicines 2022;10:1410. [DOI: 10.3390/biomedicines10061410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang L, Zhao Q, Cang H, Wang Z, Hu X, Pan R, Yang Y, Chen Y. Acute Myeloid Leukemia Cells Educate Mesenchymal Stromal Cells toward an Adipogenic Differentiation Propensity with Leukemia Promotion Capabilities. Adv Sci (Weinh) 2022;9:2105811. [PMID: 35686138 DOI: 10.1002/advs.202105811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ruiz-aparicio PF, Vernot J. Bone Marrow Aging and the Leukaemia-Induced Senescence of Mesenchymal Stem/Stromal Cells: Exploring Similarities. JPM 2022;12:716. [DOI: 10.3390/jpm12050716] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Sidorova OA, Sayed S, Paszkowski-Rogacz M, Seifert M, Camgöz A, Roeder I, Bornhäuser M, Thiede C, Buchholz F. RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations. Cells 2022;11:854. [PMID: 35269477 DOI: 10.3390/cells11050854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Herbst SA, Kim V, Schitter EC, Bruch P, Roider T, Liebers N, Kolb C, Knoll M, Lu J, Dreger P, Müller-tidow C, Zenz T, Huber W, Dietrich S. Imaging-based coculture model for high-throughput compound screening in hematological cancers.. [DOI: 10.1101/2022.02.18.481065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ganesan S, Mathews V, Vyas N. Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough? Int J Cancer 2021. [PMID: 34921734 DOI: 10.1002/ijc.33908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
15 Bobrova NM, Romanovskaya TV. Mechanisms of Drug Resistance in Acute Myeloid Leukemia. Biol Bull Rev 2021;11:32-46. [DOI: 10.1134/s2079086421070021] [Reference Citation Analysis]
16 Ciciarello M, Corradi G, Forte D, Cavo M, Curti A. Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance? Cancers (Basel) 2021;13:5319. [PMID: 34771483 DOI: 10.3390/cancers13215319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Gynn LE, Anderson E, Robinson G, Wexler SA, Upstill-Goddard G, Cox C, May JE. Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, whilst leukaemic cells are protected. Mutagenesis 2021:geab033. [PMID: 34505878 DOI: 10.1093/mutage/geab033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yao Y, Li F, Huang J, Jin J, Wang H. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Exp Hematol Oncol 2021;10:39. [PMID: 34246314 DOI: 10.1186/s40164-021-00233-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
19 Li B, Jia R, Li W, Zhou Y, Guo D, Teng Q, Du S, Li M, Li W, Sun T, Ma D, Ji M, Ji C. PAK1 Mediates Bone Marrow Stromal Cell-Induced Drug Resistance in Acute Myeloid Leukemia via ERK1/2 Signaling Pathway. Front Cell Dev Biol 2021;9:686695. [PMID: 34307365 DOI: 10.3389/fcell.2021.686695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Kapor S, Santibanez JF. Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies. J Clin Med 2021;10:2788. [PMID: 34202907 DOI: 10.3390/jcm10132788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
21 Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, Kaempf A, Gosline SJC, Wang YT, Hansen JR, Gritsenko MA, Hutchinson C, Weitz KK, Moon J, Cendali F, Fillmore TL, Tsai CF, Schepmoes AA, Shi T, Arshad OA, McDermott JE, Babur O, Watanabe-Smith K, Demir E, D'Alessandro A, Liu T, Tognon CE, Tyner JW, McWeeney SK, Rodland KD, Druker BJ, Traer E. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell 2021;39:999-1014.e8. [PMID: 34171263 DOI: 10.1016/j.ccell.2021.06.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 8.5] [Reference Citation Analysis]
22 Michelozzi IM, Kirtsios E, Giustacchini A. Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success. Cancers (Basel) 2021;13:2816. [PMID: 34198742 DOI: 10.3390/cancers13112816] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
23 Deeg HJ. Chimerism, the Microenvironment and Control of Leukemia. Front Immunol 2021;12:652105. [PMID: 33968052 DOI: 10.3389/fimmu.2021.652105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Li L, Zhao L, Man J, Liu B. CXCL2 benefits acute myeloid leukemia cells in hypoxia. Int J Lab Hematol 2021. [PMID: 33793061 DOI: 10.1111/ijlh.13512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Sletta KY, Castells O, Gjertsen BT. Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia. Front Oncol 2021;11:654817. [PMID: 33842370 DOI: 10.3389/fonc.2021.654817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Bai H, Wang T, Kong F, Zhang M, Li Z, Zhuang L, Ma M, Liu F, Wang C, Xu H, Gu N, Zhang Y. CXCR4 and CD44 dual-targeted Prussian blue nanosystem with daunorubicin loaded for acute myeloid leukemia therapy. Chemical Engineering Journal 2021;405:126891. [DOI: 10.1016/j.cej.2020.126891] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
27 Chong SJF, Iskandar K, Lai JXH, Qu J, Raman D, Valentin R, Herbaux C, Collins M, Low ICC, Loh T, Davids M, Pervaiz S. Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res 2020;48:12727-45. [PMID: 33245769 DOI: 10.1093/nar/gkaa1110] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
28 Yu Z, Du J, Hui H, Kan S, Huo T, Zhao K, Wu T, Guo Q, Lu N. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. Theranostics 2021;11:93-106. [PMID: 33391463 DOI: 10.7150/thno.46593] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
29 Miranda MA, Marcato PD, Mondal A, Chowdhury N, Gebeyehu A, Surapaneni SK, Bentley MVLB, Amaral R, Pan CX, Singh M. Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells. Mater Sci Eng C Mater Biol Appl 2021;119:111460. [PMID: 33321591 DOI: 10.1016/j.msec.2020.111460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
30 Janagama D, Hui SK. 3-D Cell Culture Systems in Bone Marrow Tissue and Organoid Engineering, and BM Phantoms as In Vitro Models of Hematological Cancer Therapeutics-A Review. Materials (Basel) 2020;13:E5609. [PMID: 33316977 DOI: 10.3390/ma13245609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
31 Ci T, Li H, Chen G, Wang Z, Wang J, Abdou P, Tu Y, Dotti G, Gu Z. Cryo-shocked cancer cells for targeted drug delivery and vaccination. Sci Adv 2020;6:eabc3013. [PMID: 33298439 DOI: 10.1126/sciadv.abc3013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
32 Mohammadalipour A, Dumbali SP, Wenzel PL. Mitochondrial Transfer and Regulators of Mesenchymal Stromal Cell Function and Therapeutic Efficacy. Front Cell Dev Biol 2020;8:603292. [PMID: 33365311 DOI: 10.3389/fcell.2020.603292] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
33 Khoury JD, Tashakori M, Yang H, Loghavi S, Wang Y, Wang J, Piya S, Borthakur G. Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. Cancers (Basel) 2020;12:E3511. [PMID: 33255818 DOI: 10.3390/cancers12123511] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
34 Cao H, Gao Y, Wang R, Guo Q, Hui H. Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment. Ann Transl Med 2020;8:1046. [PMID: 33145265 DOI: 10.21037/atm-20-1166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Cucchi DGJ, Groen RWJ, Janssen JJWM, Cloos J. Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome. Drug Resist Updat 2020;53:100730. [PMID: 33096284 DOI: 10.1016/j.drup.2020.100730] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
36 Harada T, Tsuboi I, Utsunomiya M, Yasuda M, Aizawa S. Kinetics of leukemic cells in 3D culture with stromal cells and with arginine deprivation stress. J Biosci Bioeng 2020;130:650-8. [PMID: 32861594 DOI: 10.1016/j.jbiosc.2020.07.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Deeg HJ, Salit RB, Monahan T, Schoch G, McFarland C, Scott BL, Storer BE. Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis. Biol Blood Marrow Transplant 2020;26:2197-203. [PMID: 32693211 DOI: 10.1016/j.bbmt.2020.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Biomed Pharmacother 2020;129:110390. [PMID: 32563150 DOI: 10.1016/j.biopha.2020.110390] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
39 Pievani A, Biondi M, Tomasoni C, Biondi A, Serafini M. Location First: Targeting Acute Myeloid Leukemia Within Its Niche. J Clin Med 2020;9:E1513. [PMID: 32443460 DOI: 10.3390/jcm9051513] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
40 Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl VM, Beaver L, Mims A, Puduvalli VK, Blachly JS, Lehman A, Harrington B, Henderson S, Breitbach JT, Williams KE, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Adv. 2019;3:242-255. [PMID: 30692102 DOI: 10.1182/bloodadvances.2018024182] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
41 Singh AK, Cancelas JA. Gap Junctions in the Bone Marrow Lympho-Hematopoietic Stem Cell Niche, Leukemia Progression, and Chemoresistance. Int J Mol Sci 2020;21:E796. [PMID: 31991829 DOI: 10.3390/ijms21030796] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
42 Almeida-Porada G, Atala AJ, Porada CD. Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery. Mol Ther Methods Clin Dev 2020;16:204-24. [PMID: 32071924 DOI: 10.1016/j.omtm.2020.01.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
43 Ikumawoyi VO, Awodele O, Agbaje EO, Alimba CG, Bakare AA, Akinloye O. Bioactivity and modulatory functions of Napoleona vogelii on oxidative stress-induced micronuclei and apoptotic biomarkers in mice. Toxicol Rep 2019;6:963-74. [PMID: 31673498 DOI: 10.1016/j.toxrep.2019.09.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Ciciarello M, Corradi G, Loscocco F, Visani G, Monaco F, Cavo M, Curti A, Isidori A. The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia. Front Oncol. 2019;9:1135. [PMID: 31709192 DOI: 10.3389/fonc.2019.01135] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
45 Kouzi F, Zibara K, Bourgeais J, Picou F, Gallay N, Brossaud J, Dakik H, Roux B, Hamard S, Le Nail LR, Hleihel R, Foucault A, Ravalet N, Rouleux-Bonnin F, Gouilleux F, Mazurier F, Bene MC, Akl H, Gyan E, Domenech J, El-Sabban M, Herault O. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. Oncogene 2020;39:1198-212. [PMID: 31649334 DOI: 10.1038/s41388-019-1069-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
46 Li H, Li J, Cheng J, Chen X, Zhou L, Li Z. AML‑derived mesenchymal stem cells upregulate CTGF expression through the BMP pathway and induce K562‑ADM fusiform transformation and chemoresistance. Oncol Rep 2019;42:1035-46. [PMID: 31322275 DOI: 10.3892/or.2019.7237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
47 Cao T, Ye Y, Liao H, Shuai X, Jin Y, Su J, Zheng Q. Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia. Medicine (Baltimore) 2019;98:e15948. [PMID: 31169718 DOI: 10.1097/MD.0000000000015948] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
48 Michelozzi IM, Granata V, De Ponti G, Alberti G, Tomasoni C, Antolini L, Gambacorti-Passerini C, Gentner B, Dazzi F, Biondi A, Coliva T, Rizzari C, Pievani A, Serafini M. Acute myeloid leukaemia niche regulates response to L-asparaginase. Br J Haematol 2019;186:420-30. [PMID: 31044436 DOI: 10.1111/bjh.15920] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
49 Zhang Z, Liang X, Fan Y, Gao Z, Bindoff LA, Costea DE, Li L. Fibroblasts rescue oral squamous cancer cell from metformin-induced apoptosis via alleviating metabolic disbalance and inhibiting AMPK pathway. Cell Cycle 2019;18:949-62. [PMID: 31014173 DOI: 10.1080/15384101.2019.1598727] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
50 Kaspers GJL. Acute myeloid leukaemia niche regulates response to L-asparaginase. Br J Haematol 2019;186:397-9. [PMID: 31020655 DOI: 10.1111/bjh.15924] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 Xiao P, Sandhow L, Heshmati Y, Kondo M, Bouderlique T, Dolinska M, Johansson AS, Sigvardsson M, Ekblom M, Walfridsson J, Qian H. Distinct roles of mesenchymal stem and progenitor cells during the development of acute myeloid leukemia in mice. Blood Adv 2018;2:1480-94. [PMID: 29945938 DOI: 10.1182/bloodadvances.2017013870] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
52 Cao H, Li W, Zhou Y, Tan R, Yang Y, Zhou Y, Guo Q, Zhao L. Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway. Front Oncol 2019;9:188. [PMID: 31024831 DOI: 10.3389/fonc.2019.00188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
53 Ullah M, Azazzen D, Kaci R, Benabbou N, Pujade Lauraine E, Pocard M, Mirshahi M. High Expression of HLA-G in Ovarian Carcinomatosis: The Role of Interleukin-1β. Neoplasia 2019;21:331-42. [PMID: 30802770 DOI: 10.1016/j.neo.2019.01.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
54 Castelli G, Pelosi E, Testa U. Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. Cancers (Basel) 2019;11:E260. [PMID: 30813354 DOI: 10.3390/cancers11020260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
55 Chen T, Zhang G, Kong L, Xu S, Wang Y, Dong M. Leukemia-derived exosomes induced IL-8 production in bone marrow stromal cells to protect the leukemia cells against chemotherapy. Life Sci 2019;221:187-95. [PMID: 30716336 DOI: 10.1016/j.lfs.2019.02.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
56 Lee MW, Ryu S, Kim DS, Lee JW, Sung KW, Koo HH, Yoo KH. Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges. Leukemia. 2019;33:597-611. [PMID: 30705410 DOI: 10.1038/s41375-018-0373-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 14.5] [Reference Citation Analysis]
57 Lopez-Millan B, Sanchéz-Martínez D, Roca-Ho H, Gutiérrez-Agüera F, Molina O, Diaz de la Guardia R, Torres-Ruiz R, Fuster JL, Ballerini P, Suessbier U, Nombela-Arrieta C, Bueno C, Menéndez P. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia 2019;33:1557-69. [PMID: 30635633 DOI: 10.1038/s41375-018-0353-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
58 Maan ZN, Borrelli MR, Houschyar KS, Gurtner GC. Stromal Cell-Derived Factor 1 (SDF-1) Signaling and Tissue Homeostasis. Regenerative Medicine and Plastic Surgery 2019. [DOI: 10.1007/978-3-030-19958-6_6] [Reference Citation Analysis]
59 Zhang S, Xiong Y, Zhang Y, Zhao H. Targeting of mTORC1/2 by dihydroevocarpine induces cytotoxicity in acute myeloid leukemia. J Cell Physiol 2019;234:13032-41. [PMID: 30548613 DOI: 10.1002/jcp.27974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
60 Lee MW, Park YJ, Kim DS, Park HJ, Jung HL, Lee JW, Sung KW, Koo HH, Yoo KH. Human Adipose Tissue Stem Cells Promote the Growth of Acute Lymphoblastic Leukemia Cells in NOD/SCID Mice. Stem Cell Rev Rep 2018;14:451-60. [PMID: 29594684 DOI: 10.1007/s12015-018-9806-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
61 Christodoulou I, Goulielmaki M, Devetzi M, Panagiotidis M, Koliakos G, Zoumpourlis V. Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. Stem Cell Res Ther 2018;9:336. [PMID: 30526687 DOI: 10.1186/s13287-018-1078-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
62 O' Reilly E, Dhami SPS, Baev DV, Ortutay C, Halpin-McCormick A, Morrell R, Santocanale C, Samali A, Quinn J, O'Dwyer ME, Szegezdi E. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML. Sci Rep. 2018;8:15752. [PMID: 30361682 DOI: 10.1038/s41598-018-33982-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
63 Luciani GM, Xie L, Dilworth D, Tierens A, Moskovitz Y, Murison A, Szewczyk MM, Mitchell A, Lupien M, Shlush L, Dick JE, Arrowsmith CH, Barsyte-Lovejoy D, Minden MD. Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression. Exp Hematol 2019;69:27-36. [PMID: 30352278 DOI: 10.1016/j.exphem.2018.10.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
64 Khare N, Chandra S. Stevioside mediated chemosensitization studies and cytotoxicity assay on breast cancer cell lines MDA-MB-231 and SKBR3. Saudi J Biol Sci 2019;26:1596-601. [PMID: 31762632 DOI: 10.1016/j.sjbs.2018.10.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
65 de Alvarenga EC, Silva WN, Vasconcellos R, Paredes-Gamero EJ, Mintz A, Birbrair A. Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression. Ann Hematol 2018;97:1749-55. [PMID: 30069705 DOI: 10.1007/s00277-018-3463-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
66 Schürch CM. Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions. Front Oncol 2018;8:152. [PMID: 29868474 DOI: 10.3389/fonc.2018.00152] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
67 Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors. Haematologica 2018;103:1288-97. [PMID: 29773600 DOI: 10.3324/haematol.2018.188193] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
68 Hu X, Mei S, Meng W, Xue S, Jiang L, Yang Y, Hui L, Chen Y, Guan MX. CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance. Cancer Lett 2018;425:1-12. [PMID: 29574276 DOI: 10.1016/j.canlet.2018.03.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
69 Salvestrini V, Orecchioni S, Talarico G, Reggiani F, Mazzetti C, Bertolini F, Orioli E, Adinolfi E, Di Virgilio F, Pezzi A, Cavo M, Lemoli RM, Curti A. Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. Oncotarget 2017;8:5895-908. [PMID: 27980223 DOI: 10.18632/oncotarget.13927] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
70 Yu N, Seedhouse C, Russell N, Pallis M. Quantitative assessment of the sensitivity of dormant AML cells to the BAD mimetics ABT-199 and ABT-737. Leuk Lymphoma 2018;59:2447-53. [PMID: 29431553 DOI: 10.1080/10428194.2018.1434884] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
71 Wen L, Xiao B, Shi Y, Han F. PERK signalling pathway mediates single prolonged stress-induced dysfunction of medial prefrontal cortex neurons. Apoptosis 2017;22:753-68. [PMID: 28391375 DOI: 10.1007/s10495-017-1371-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
72 Zhou J, Wang S, Sun K, Chng WJ. The emerging roles of exosomes in leukemogeneis. Oncotarget 2016;7:50698-707. [PMID: 27191983 DOI: 10.18632/oncotarget.9333] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
73 Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabanian H, Yu J, Waanders E, Iacobucci I, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Kirschner-Schwabe R, Mullighan CG, Rabadan R, Ferrando AA. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature 2018;553:511-4. [PMID: 29342136 DOI: 10.1038/nature25186] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 14.2] [Reference Citation Analysis]
74 Doron B, Handu M, Kurre P. Concise Review: Adaptation of the Bone Marrow Stroma in Hematopoietic Malignancies: Current Concepts and Models: Leukemic Adaptation of the BM Niche. Stem Cells 2018;36:304-12. [DOI: 10.1002/stem.2761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
75 Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med 2016;8:355ra117. [PMID: 27605552 DOI: 10.1126/scitranslmed.aag1180] [Cited by in Crossref: 94] [Cited by in F6Publishing: 102] [Article Influence: 15.7] [Reference Citation Analysis]
76 Lam SS, Ho ES, He BL, Wong WW, Cher CY, Ng NK, Man CH, Gill H, Cheung AM, Ip HW, So CC, Tamburini J, So CW, Ho DN, Au CH, Chan TL, Ma ES, Liang R, Kwong YL, Leung AY. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Sci Transl Med 2016;8:359ra129. [PMID: 27708062 DOI: 10.1126/scitranslmed.aaf3735] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
77 Di Tullio A, Rouault-Pierre K, Abarrategi A, Mian S, Grey W, Gribben J, Stewart A, Blackwood E, Bonnet D. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun 2017;8:1679. [PMID: 29162833 DOI: 10.1038/s41467-017-01834-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
78 Nimmagadda SC, Frey S, Edelmann B, Hellmich C, Zaitseva L, König GM, Kostenis E, Bowles KM, Fischer T. Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia. Leukemia 2018;32:846-9. [PMID: 29109446 DOI: 10.1038/leu.2017.324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
79 Sterner RM, Kremer KN, Al-Kali A, Patnaik MM, Gangat N, Litzow MR, Kaufmann SH, Westendorf JJ, van Wijnen AJ, Hedin KE. Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. Oncotarget 2017;8:94569-79. [PMID: 29212250 DOI: 10.18632/oncotarget.21809] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
80 Ozdogan H, Gur Dedeoglu B, Oztemur Islakoglu Y, Aydos A, Kose S, Atalay A, Yegin ZA, Avcu F, Uckan Cetinkaya D, Ilhan O. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia. Leuk Res 2017;63:62-71. [PMID: 29102598 DOI: 10.1016/j.leukres.2017.10.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
81 Her Z, Yong KSM, Paramasivam K, Tan WWS, Chan XY, Tan SY, Liu M, Fan Y, Linn YC, Hui KM, Surana U, Chen Q. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia. J Hematol Oncol 2017;10:162. [PMID: 28985760 DOI: 10.1186/s13045-017-0532-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
82 Long X, Gerbing RB, Alonzo TA, Redell MS. Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children's Oncology Group report. Oncotarget 2017;8:90037-49. [PMID: 29163809 DOI: 10.18632/oncotarget.21363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
83 Macanas-Pirard P, Broekhuizen R, González A, Oyanadel C, Ernst D, García P, Montecinos VP, Court F, Ocqueteau M, Ramirez P, Nervi B. Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome. Oncotarget 2017;8:23073-86. [PMID: 28160570 DOI: 10.18632/oncotarget.14981] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
84 Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury JD, Cortes J, Andreeff M, Post SM. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms. Haematologica 2017;102:2048-57. [PMID: 28912176 DOI: 10.3324/haematol.2017.168856] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
85 Wang W, Bochtler T, Wuchter P, Manta L, He H, Eckstein V, Ho AD, Lutz C. Mesenchymal stromal cells contribute to quiescence of therapy-resistant leukemic cells in acute myeloid leukemia. Eur J Haematol 2017;99:392-8. [PMID: 28800175 DOI: 10.1111/ejh.12934] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
86 Shah NN. Antibody Based Therapies in Acute Leukemia. Curr Drug Targets 2017;18:257-70. [PMID: 27593687 DOI: 10.2174/1389450117666160905091459] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
87 Yang H, Wang L, Sun H, He X, Zhang J, Liu F. Anticancer activity in vitro and biological safety evaluation in vivo of Sika deer antler protein. J Food Biochem 2017;41:e12421. [DOI: 10.1111/jfbc.12421] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
88 Tsou LK, Huang YH, Song JS, Ke YY, Huang JK, Shia KS. Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology. Med Res Rev 2018;38:1188-234. [PMID: 28768055 DOI: 10.1002/med.21464] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
89 Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Rao A, Al-Atrash G, Konopleva M, Davis RE, Harrington MA, Cahill CW, Bueso-Ramos C, Andreeff M. AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. JCI Insight 2017;2:90036. [PMID: 28679949 DOI: 10.1172/jci.insight.90036] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 11.3] [Reference Citation Analysis]
90 Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 2017;102:1537-48. [PMID: 28659338 DOI: 10.3324/haematol.2016.162230] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
91 Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 2017;130:789-802. [PMID: 28619982 DOI: 10.1182/blood-2016-02-699363] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 11.5] [Reference Citation Analysis]
92 Schito L, Rey S, Konopleva M. Integration of hypoxic HIF-α signaling in blood cancers. Oncogene 2017;36:5331-40. [DOI: 10.1038/onc.2017.119] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
93 Diaz de la Guardia R, Lopez-Millan B, Lavoie JR, Bueno C, Castaño J, Gómez-Casares M, Vives S, Palomo L, Juan M, Delgado J, Blanco ML, Nomdedeu J, Chaparro A, Fuster JL, Anguita E, Rosu-Myles M, Menéndez P. Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes. Stem Cell Reports 2017;8:1573-86. [PMID: 28528702 DOI: 10.1016/j.stemcr.2017.04.019] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 9.5] [Reference Citation Analysis]
94 Jiang G, Liu J, Ren B, Zhang L, Owusu L, Liu L, Zhang J, Tang Y, Li W. Anti-tumor and chemosensitization effects of Cryptotanshinone extracted from Salvia miltiorrhiza Bge. on ovarian cancer cells in vitro. J Ethnopharmacol 2017;205:33-40. [PMID: 28456578 DOI: 10.1016/j.jep.2017.04.026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
95 Desbourdes L, Javary J, Charbonnier T, Ishac N, Bourgeais J, Iltis A, Chomel JC, Turhan A, Guilloton F, Tarte K, Demattei MV, Ducrocq E, Rouleux-Bonnin F, Gyan E, Hérault O, Domenech J. Alteration Analysis of Bone Marrow Mesenchymal Stromal Cells from De Novo Acute Myeloid Leukemia Patients at Diagnosis. Stem Cells Dev 2017;26:709-22. [PMID: 28394200 DOI: 10.1089/scd.2016.0295] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
96 Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia 2017;31:2065-74. [PMID: 28321124 DOI: 10.1038/leu.2017.87] [Cited by in Crossref: 56] [Cited by in F6Publishing: 63] [Article Influence: 9.3] [Reference Citation Analysis]
97 Azizidoost S, Vijay V, Cogle CR, Khodadi E, Saki N. The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia. Clin Transl Oncol 2017;19:1059-66. [DOI: 10.1007/s12094-017-1642-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
98 Brenner AK, Nepstad I, Bruserud Ø. Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms. Front Immunol 2017;8:106. [PMID: 28232835 DOI: 10.3389/fimmu.2017.00106] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
99 Le Naour A, Couderc B. Role of MSCs in Antitumor Drug Resistance. Mesenchymal Stromal Cells as Tumor Stromal Modulators 2017. [DOI: 10.1016/b978-0-12-803102-5.00013-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
100 Korn C, Méndez-Ferrer S. Myeloid malignancies and the microenvironment. Blood 2017;129:811-22. [PMID: 28064238 DOI: 10.1182/blood-2016-09-670224] [Cited by in Crossref: 99] [Cited by in F6Publishing: 107] [Article Influence: 14.1] [Reference Citation Analysis]
101 von der Heide EK, Neumann M, Vosberg S, James AR, Schroeder MP, Ortiz-Tanchez J, Isaakidis K, Schlee C, Luther M, Jöhrens K, Anagnostopoulos I, Mochmann LH, Nowak D, Hofmann WK, Greif PA, Baldus CD. Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients. Leukemia 2017;31:1069-78. [PMID: 27833093 DOI: 10.1038/leu.2016.324] [Cited by in Crossref: 56] [Cited by in F6Publishing: 63] [Article Influence: 8.0] [Reference Citation Analysis]
102 Prakash MD, Miller S, Randall-Demllo S, Nurgali K. Mesenchymal Stem Cell Treatment of Inflammation-Induced Cancer. Inflamm Bowel Dis 2016;22:2694-703. [PMID: 27753693 DOI: 10.1097/MIB.0000000000000900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
103 Tian C, Zheng G, Zhuang H, Li X, Hu D, Zhu L, Wang T, You MJ, Zhang Y. MicroRNA-494 Activation Suppresses Bone Marrow Stromal Cell-Mediated Drug Resistance in Acute Myeloid Leukemia Cells: ROLE OF MicroRNA-494 IN DRUG RESISTANCE OF AML. J Cell Physiol 2017;232:1387-95. [DOI: 10.1002/jcp.25628] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
104 Ganesan S, Alex AA, Chendamarai E, Balasundaram N, Palani HK, David S, Kulkarni U, Aiyaz M, Mugasimangalam R, Korula A, Abraham A, Srivastava A, Padua RA, Chomienne C, George B, Balasubramanian P, Mathews V. Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 2016;30:2169-78. [PMID: 27560113 DOI: 10.1038/leu.2016.227] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
105 Zhou HS, Carter BZ, Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med. 2016;13:248-259. [PMID: 27458532 DOI: 10.20892/j.issn.2095-3941.2016.0023] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 10.7] [Reference Citation Analysis]
106 Smith ML, Chyla B, McKeegan E, Tahir SK. Development of a flow cytometric method for quantification of BCL-2 family members in chronic lymphocytic leukemia and correlation with sensitivity to BCL-2 family inhibitors. Cytometry B Clin Cytom 2017;92:331-9. [PMID: 27177607 DOI: 10.1002/cyto.b.21383] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
107 Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, Saland E, Castellano R, Pouyet L, Collette Y, Vey N, Chabannon C, Recher C, Sarry JE, Alcor D, Peyron JF, Griessinger E. Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood 2016;128:253-64. [PMID: 27257182 DOI: 10.1182/blood-2015-07-655860] [Cited by in Crossref: 236] [Cited by in F6Publishing: 246] [Article Influence: 33.7] [Reference Citation Analysis]
108 Matsuo H, Nakamura N, Tomizawa D, Saito AM, Kiyokawa N, Horibe K, Nishinaka-Arai Y, Tokumasu M, Itoh H, Kamikubo Y, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Tanaka S, Adachi S. CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 2016;63:1394-9. [PMID: 27135782 DOI: 10.1002/pbc.26035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
109 Bernasconi P, Farina M, Boni M, Dambruoso I, Calvello C. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor? Am J Hematol 2016;91:507-17. [PMID: 26822317 DOI: 10.1002/ajh.24312] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
110 Choi WT, Yang Y, Xu Y, An J. Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis. Curr Top Med Chem 2014;14:1574-89. [PMID: 25159167 DOI: 10.2174/1568026614666140827143541] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
111 Rieger CT, Fiegl M. Microenvironmental oxygen partial pressure in acute myeloid leukemia: Is there really a role for hypoxia? Exp Hematol 2016;44:578-82. [PMID: 27118044 DOI: 10.1016/j.exphem.2016.04.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
112 Lye KL, Nordin N, Vidyadaran S, Thilakavathy K. Mesenchymal stem cells: From stem cells to sarcomas. Cell Biol Int. 2016;40:610-618. [PMID: 26992453 DOI: 10.1002/cbin.10603] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
113 Shen ZH, Zeng DF, Kong PY, Ma YY, Zhang X. AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds. Blood Cells Mol Dis 2016;59:16-24. [PMID: 27282562 DOI: 10.1016/j.bcmd.2016.03.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
114 Lee JY, Han AR, Lee SE, Min WS, Kim HJ. Co-culture with podoplanin+ cells protects leukemic blast cells with leukemia-associated antigens in the tumor microenvironment. Mol Med Rep 2016;13:3849-57. [PMID: 27035421 DOI: 10.3892/mmr.2016.5009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
115 Bakker E, Qattan M, Mutti L, Demonacos C, Krstic-demonacos M. The role of microenvironment and immunity in drug response in leukemia. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2016;1863:414-26. [DOI: 10.1016/j.bbamcr.2015.08.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
116 Kuett A, Rieger C, Perathoner D, Herold T, Wagner M, Sironi S, Sotlar K, Horny HP, Deniffel C, Drolle H, Fiegl M. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia. Sci Rep 2015;5:18411. [PMID: 26674118 DOI: 10.1038/srep18411] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
117 Marjon KD, Termini CM, Karlen KL, Saito-Reis C, Soria CE, Lidke KA, Gillette JM. Tetraspanin CD82 regulates bone marrow homing of acute myeloid leukemia by modulating the molecular organization of N-cadherin. Oncogene 2016;35:4132-40. [PMID: 26592446 DOI: 10.1038/onc.2015.449] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
118 Li X, Guo H, Duan H, Yang Y, Meng J, Liu J, Wang C, Xu H. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis. Sci Rep 2015;5:16228. [PMID: 26538086 DOI: 10.1038/srep16228] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
119 Kumar B, Garcia M, Murakami JL, Chen CC. Exosome-mediated microenvironment dysregulation in leukemia. Biochim Biophys Acta. 2015; Sep 15. [Epub ahead of print]. [PMID: 26384870 DOI: 10.1016/j.bbamcr.2015.09.017] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 5.8] [Reference Citation Analysis]
120 Binato R, de Almeida Oliveira NC, Du Rocher B, Abdelhay E. The molecular signature of AML mesenchymal stromal cells reveals candidate genes related to the leukemogenic process. Cancer Lett 2015;369:134-43. [PMID: 26279521 DOI: 10.1016/j.canlet.2015.08.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
121 Sison EA, Magoon D, Li L, Annesley CE, Rau RE, Small D, Brown P. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget 2014;5:8947-58. [PMID: 25333254 DOI: 10.18632/oncotarget.2407] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
122 Low JH, Ramdas P, Radhakrishnan AK. Modulatory effects of mesenchymal stem cells on leucocytes and leukemic cells: A double-edged sword? Blood Cells Mol Dis 2015;55:351-7. [PMID: 26460259 DOI: 10.1016/j.bcmd.2015.07.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
123 Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, Simkin I, Yuan J, Antonakos B, Barys L, Ito M, Stone R, Galinsky I, Cowens K, Nelson E, Sattler M, Jeay S, Wuerthner JU, McDonough SM, Wiesmann M, Griffin JD. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. Mol Cancer Ther 2015;14:2249-59. [PMID: 26206331 DOI: 10.1158/1535-7163.MCT-15-0429] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
124 Zhou HB, Chen JM, Shao LM, Chen ZG. Apoptosis of human pancreatic carcinoma cell-1 cells induced by Yin Chen Hao Decoction. World J Gastroenterol 2015; 21(27): 8352-8357 [PMID: 26217086 DOI: 10.3748/wjg.v21.i27.8352] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
125 Sivagnanalingam U, Balys M, Eberhardt A, Wang N, Myers JR, Ashton JM, Becker MW, Calvi LM, Mendler JH. Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia. PLoS One 2015;10:e0132375. [PMID: 26177509 DOI: 10.1371/journal.pone.0132375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
126 Drolle H, Wagner M, Vasold J, Kütt A, Deniffel C, Sotlar K, Sironi S, Herold T, Rieger C, Fiegl M. Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy. Leukemia Research 2015;39:779-85. [DOI: 10.1016/j.leukres.2015.04.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
127 Lee JY, Kim DC, Kim H. Humanized (SCID) Mice as a Model to Study human Leukemia. BSL 2015;21:51-59. [DOI: 10.15616/bsl.2015.21.2.51] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
128 Hendijani F, Haghjooy Javanmard S, Sadeghi-aliabadi H. Human Wharton's jelly mesenchymal stem cell secretome display antiproliferative effect on leukemia cell line and produce additive cytotoxic effect in combination with doxorubicin. Tissue and Cell 2015;47:229-34. [DOI: 10.1016/j.tice.2015.01.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
129 Long X, Yu Y, Perlaky L, Man TK, Redell MS. Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia. Br J Haematol 2015;170:704-18. [PMID: 25974135 DOI: 10.1111/bjh.13492] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
130 Liesveld J. Plerixafor: potential role in acute leukemia therapy. Expert Opinion on Orphan Drugs 2015;3:467-475. [DOI: 10.1517/21678707.2015.1020297] [Reference Citation Analysis]
131 Yang X, Yu DD, Yan F, Jing YY, Han ZP, Sun K, Liang L, Hou J, Wei LX. The role of autophagy induced by tumor microenvironment in different cells and stages of cancer. Cell Biosci. 2015;5:14. [PMID: 25844158 DOI: 10.1186/s13578-015-0005-2] [Cited by in Crossref: 93] [Cited by in F6Publishing: 97] [Article Influence: 11.6] [Reference Citation Analysis]
132 Ghiaur G, Wroblewski M, Loges S. Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation. Semin Hematol 2015;52:200-6. [PMID: 26111467 DOI: 10.1053/j.seminhematol.2015.03.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
133 Zou J, Hong Y, Tong Y, Wei J, Qin Y, Shao S, Wang C, Zhou K. Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome. Stem Cells Int 2015;2015:957502. [PMID: 25861282 DOI: 10.1155/2015/957502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
134 Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis 2014;19:698-707. [PMID: 24337870 DOI: 10.1007/s10495-013-0954-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
135 Vasold J, Wagner M, Drolle H, Deniffel C, Kütt A, Oostendorp R, Sironi S, Rieger C, Fiegl M. The bone marrow microenvironment is a critical player in the NK cell response against acute myeloid leukaemia in vitro. Leukemia Research 2015;39:257-62. [DOI: 10.1016/j.leukres.2014.12.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
136 He S, Huang Y, Wang Y, Tang J, Song Y, Yu X, Ma J, Wang S, Yin H, Li Q, Ji L, Xu X. Histamine-releasing factor/translationally controlled tumor protein plays a role in induced cell adhesion, apoptosis resistance and chemoresistance in non-Hodgkin lymphomas. Leuk Lymphoma 2015;56:2153-61. [PMID: 25363345 DOI: 10.3109/10428194.2014.981173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
137 Schlesinger M, Bendas G. Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis. Cancer Metastasis Rev 2015;34:575-91. [DOI: 10.1007/s10555-014-9545-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
138 Chitu V, Caescu CI, Stanley ER, Lennartsson J, Rönnstrand L, Heldin C. The PDGFR Receptor Family. Receptor Tyrosine Kinases: Family and Subfamilies 2015. [DOI: 10.1007/978-3-319-11888-8_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
139 Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25:198-213. [PMID: 25540894 DOI: 10.1016/j.tcb.2014.11.006] [Cited by in Crossref: 430] [Cited by in F6Publishing: 374] [Article Influence: 47.8] [Reference Citation Analysis]
140 Reikvam H, Ryningen A, Sæterdal LR, Nepstad I, Foss B, Bruserud Ø. Connexin expression in human acute myeloid leukemia cells: identification of patient subsets based on protein and global gene expression profiles. Int J Mol Med 2015;35:645-52. [PMID: 25529637 DOI: 10.3892/ijmm.2014.2045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
141 Li X, Guo H, Yang Y, Meng J, Liu J, Wang C, Xu H. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo. Sci Rep 2014;4:6610. [PMID: 25312253 DOI: 10.1038/srep06610] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
142 Liu R, Wei S, Chen J, Xu S. Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications. Cancer Letters 2014;353:145-52. [DOI: 10.1016/j.canlet.2014.07.047] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
143 Isidori A, Salvestrini V, Ciciarello M, Loscocco F, Visani G, Parisi S, Lecciso M, Ocadlikova D, Rossi L, Gabucci E, Clissa C, Curti A. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev Hematol 2014;7:807-18. [PMID: 25227702 DOI: 10.1586/17474086.2014.958464] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
144 Abe-suzuki S, Kurata M, Abe S, Onishi I, Kirimura S, Nashimoto M, Murayama T, Hidaka M, Kitagawa M. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes. Lab Invest 2014;94:1212-23. [DOI: 10.1038/labinvest.2014.110] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
145 Boyd AL, Campbell CJ, Hopkins CI, Fiebig-Comyn A, Russell J, Ulemek J, Foley R, Leber B, Xenocostas A, Collins TJ, Bhatia M. Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. J Exp Med 2014;211:1925-35. [PMID: 25180064 DOI: 10.1084/jem.20140131] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
146 Tavernier E, Aanei C, Solly F, Flandrin-Gresta P, Campos L, Guyotat D. [CXCR4: a new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia]. Bull Cancer 2014;101:593-604. [PMID: 24977448 DOI: 10.1684/bdc.2014.1925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
147 Boyd AL, Bhatia M. Bone marrow localization and functional properties of human hematopoietic stem cells: . Current Opinion in Hematology 2014;21:249-55. [DOI: 10.1097/moh.0000000000000055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
148 Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014;13:217-236. [PMID: 24577402 DOI: 10.1038/nrd4236] [Cited by in Crossref: 480] [Cited by in F6Publishing: 555] [Article Influence: 53.3] [Reference Citation Analysis]
149 Kremer KN, Dudakovic A, Mcgee-lawrence ME, Philips RL, Hess AD, Smith BD, van Wijnen AJ, Karp JE, Kaufmann SH, Westendorf JJ, Hedin KE. Osteoblasts Protect AML Cells From SDF-1-Induced Apoptosis: OSTEOBLASTS PROTECT AML CELLS. J Cell Biochem 2014;115:1128-37. [DOI: 10.1002/jcb.24755] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
150 Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst. 2014;106:djt440. [PMID: 24526787 DOI: 10.1093/jnci/djt440] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 6.2] [Reference Citation Analysis]
151 Fidler JM, An J, Carter BZ, Andreeff M. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol 2014;73:961-74. [PMID: 24619497 DOI: 10.1007/s00280-014-2428-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
152 Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, Wang Y, Battula VL, Mak PY, Schallmoser K, Ruvolo P, Schober WD, Shpall EJ, Nguyen MH, Strunk D, Bueso-Ramos CE, Konoplev S, Davis RE, Konopleva M, Andreeff M. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood 2014;123:2691-702. [PMID: 24599548 DOI: 10.1182/blood-2013-06-511527] [Cited by in Crossref: 175] [Cited by in F6Publishing: 192] [Article Influence: 19.4] [Reference Citation Analysis]
153 Lee HK, Kim HW, Lee IY, Lee J, Lee J, Jung DS, Lee SY, Park SH, Hwang H, Choi JS, Kim JH, Kim SW, Kim JK, Cools J, Koh JS, Song HJ. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood 2014;123:2209-19. [PMID: 24532805 DOI: 10.1182/blood-2013-04-493916] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
154 August KJ, Narendran A, Neville KA. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions. Drugs 2013;73:439-61. [PMID: 23568274 DOI: 10.1007/s40265-013-0026-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
155 Sankaranarayanan K, Ramachandran RP, Sundararajan R. Electrically-enhanced proliferation control of cancer-stem-cells-like adult human mesenchymal stem cells – a novel modality of treatment. Electroporation-Based Therapies for Cancer. Elsevier; 2014. pp. 127-59. [DOI: 10.1533/9781908818294.127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
156 Civini S, Jin P, Ren J, Sabatino M, Castiello L, Jin J, Wang H, Zhao Y, Marincola F, Stroncek D. Leukemia cells induce changes in human bone marrow stromal cells. J Transl Med 2013;11:298. [PMID: 24304929 DOI: 10.1186/1479-5876-11-298] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
157 Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 2013;45:e54. [PMID: 24232253 DOI: 10.1038/emm.2013.94] [Cited by in Crossref: 786] [Cited by in F6Publishing: 819] [Article Influence: 78.6] [Reference Citation Analysis]
158 Li X, Deeg HJ. Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells. Exp Hematol 2014;42:4-10. [PMID: 24125777 DOI: 10.1016/j.exphem.2013.10.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
159 Malfuson JV, Boutin L, Clay D, Thépenier C, Desterke C, Torossian F, Guerton B, Anginot A, de Revel T, Lataillade JJ, Le Bousse-Kerdilès MC. SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis. Leukemia 2014;28:853-64. [PMID: 23999380 DOI: 10.1038/leu.2013.256] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
160 Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 2013;122:2443-52. [PMID: 23982172 DOI: 10.1182/blood-2013-03-491431] [Cited by in Crossref: 148] [Cited by in F6Publishing: 160] [Article Influence: 14.8] [Reference Citation Analysis]
161 Wu KN, Zhao YM, He Y, Wang BS, Du KL, Fu S, Hu KM, Zhang LF, Liu LZ, Hu YX, Wang YJ, Huang H. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways. Leuk Lymphoma 2014;55:668-76. [PMID: 23741975 DOI: 10.3109/10428194.2013.811579] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
162 Jin L, Tabe Y, Kojima K, Shikami M, Benito J, Ruvolo V, Wang RY, McQueen T, Ciurea SO, Miida T, Andreeff M, Konopleva M. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. J Mol Med (Berl) 2013;91:1383-97. [PMID: 23955073 DOI: 10.1007/s00109-013-1076-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
163 Yuan Y, Lu X, Tao CL, Chen X, Shao HW, Huang SL. Forced expression of indoleamine-2,3-dioxygenase in human umbilical cord-derived mesenchymal stem cells abolishes their anti-apoptotic effect on leukemia cell lines in vitro. In Vitro Cell Dev Biol Anim 2013;49:752-8. [PMID: 23949777 DOI: 10.1007/s11626-013-9667-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
164 Tabe Y, Shi YX, Zeng Z, Jin L, Shikami M, Hatanaka Y, Miida T, Hsu FJ, Andreeff M, Konopleva M. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One 2013;8:e62785. [PMID: 23826077 DOI: 10.1371/journal.pone.0062785] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
165 Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest. 2013;123:2395-2407. [PMID: 23676502 DOI: 10.1172/jci66553] [Cited by in Crossref: 145] [Cited by in F6Publishing: 152] [Article Influence: 14.5] [Reference Citation Analysis]
166 Li X, Marcondes AM, Ragoczy T, Telling A, Deeg HJ. Effect of intravenous coadministration of human stroma cell lines on engraftment of long-term repopulating clonal myelodysplastic syndrome cells in immunodeficient mice. Blood Cancer J. 2013;3:e113. [PMID: 23624784 DOI: 10.1038/bcj.2013.11] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
167 Vélez J, Hail N Jr, Konopleva M, Zeng Z, Kojima K, Samudio I, Andreeff M. Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells. Front Oncol 2013;3:67. [PMID: 23565503 DOI: 10.3389/fonc.2013.00067] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
168 Falavigna A, da Costa JC. Mesenchymal autologous stem cells. World Neurosurg 2015;83:236-50. [PMID: 23402865 DOI: 10.1016/j.wneu.2013.02.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Smith KM, Jamieson CHM. Therapeutics against Cancer Stem Cells: Targeting the Root of Cancer. Encyclopedia of Molecular Cell Biology and Molecular Medicine 2013. [DOI: 10.1002/3527600906.mcb.201200014] [Reference Citation Analysis]
170 Li Y, Han F, Shi Y. Increased neuronal apoptosis in medial prefrontal cortex is accompanied with changes of Bcl-2 and Bax in a rat model of post-traumatic stress disorder. J Mol Neurosci 2013;51:127-37. [PMID: 23381833 DOI: 10.1007/s12031-013-9965-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
171 de Oliveira FM, Lucena-araujo AR, Favarin MDC, Bonini Palma PV, Rego EM, Falcão RP, Covas DT, Fontes AM. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH. Experimental Hematology 2013;41:198-208. [DOI: 10.1016/j.exphem.2012.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
172 Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, Bhatia R. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood 2013;121:1824-38. [PMID: 23299311 DOI: 10.1182/blood-2012-02-412890] [Cited by in Crossref: 185] [Cited by in F6Publishing: 197] [Article Influence: 18.5] [Reference Citation Analysis]
173 Sison EA, Rau RE, McIntyre E, Li L, Small D, Brown P. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol 2013;160:785-97. [PMID: 23294096 DOI: 10.1111/bjh.12205] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
174 Welschinger R, Liedtke F, Basnett J, Dela Pena A, Juarez JG, Bradstock KF, Bendall LJ. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol. 2013;41:293-302.e1. [PMID: 23178377 DOI: 10.1016/j.exphem.2012.11.004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
175 Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 2012;3:371-94. [PMID: 22564882 DOI: 10.18632/oncotarget.477] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 7.9] [Reference Citation Analysis]
176 Thomas X. Acute myeloid leukemia in the elderly. International Journal of Hematologic Oncology 2012;1:57-69. [DOI: 10.2217/ijh.12.6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
177 Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, Thiede C, Frattini M, Nybakken GE, Pratz K, Karp J, Smith BD, Levis M. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood 2012;120:4205-14. [PMID: 23012328 DOI: 10.1182/blood-2012-01-402545] [Cited by in Crossref: 115] [Cited by in F6Publishing: 124] [Article Influence: 10.5] [Reference Citation Analysis]
178 Yi S, Chen Y, Wen L, Yang L, Cui G. Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation. Oncol Lett 2012;4:1003-7. [PMID: 23162640 DOI: 10.3892/ol.2012.884] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
179 Crews LA, Jamieson CH. Selective elimination of leukemia stem cells: hitting a moving target. Cancer Lett. 2013;338:15-22. [PMID: 22906415 DOI: 10.1016/j.canlet.2012.08.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
180 Pillozzi S, Becchetti A. Ion channels in hematopoietic and mesenchymal stem cells. Stem Cells Int 2012;2012:217910. [PMID: 22919401 DOI: 10.1155/2012/217910] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
181 Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, Kantarjian H, Lock R, Andreeff M, Konopleva M. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther 2012;13:858-70. [PMID: 22785211 DOI: 10.4161/cbt.20838] [Cited by in Crossref: 89] [Cited by in F6Publishing: 96] [Article Influence: 8.1] [Reference Citation Analysis]
182 Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 2012;120:2679-89. [PMID: 22826565 DOI: 10.1182/blood-2011-11-393934] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 7.5] [Reference Citation Analysis]
183 Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, Gray N. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia 2012;26:2233-44. [PMID: 22469781 DOI: 10.1038/leu.2012.96] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
184 Sansonetti A, Bourcier S, Durand L, Chomienne C, Smadja-joffe F, Robert-lézénès J. CD44 activation enhances acute monoblastic leukemia cell survival via Mcl-1 upregulation. Leukemia Research 2012;36:358-62. [DOI: 10.1016/j.leukres.2011.09.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
185 Medina DJ, Goodell L, Glod J, Gélinas C, Rabson AB, Strair RK. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways. Haematologica 2012;97:1255-63. [PMID: 22371181 DOI: 10.3324/haematol.2011.040659] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
186 Rao Q, Wang JY, Meng J, Tang K, Wang Y, Wang M, Xing H, Tian Z, Wang J. Low-expression of E-cadherin in leukaemia cells causes loss of homophilic adhesion and promotes cell growth. Cell Biol Int 2011;35:945-51. [PMID: 21143205 DOI: 10.1042/CBI20100456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
187 Zhang X, Ran Q, Li Z, Liu Y, Liang X, Chen X. Cell cycle arrest of Jurkat cells by leukemic bone marrow stromal cells: possible mechanisms and involvement of CRIF1. Transplant Proc 2011;43:2770-3. [PMID: 21911160 DOI: 10.1016/j.transproceed.2011.05.048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
188 Becker PS. Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment. ScientificWorldJournal 2012;2012:856467. [PMID: 22346731 DOI: 10.1100/2012/856467] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
189 To LB, Levesque JP, Herbert KE, Winkler IG, Bendall LJ, Hiwase DK, Antonenas V, Rice AM, Gottlieb D, Mills AK, Rasko JE, Larsen S, Beligaswatte A, Nilsson SK, Cooney JP, Cambareri AC, Lewis ID. Mobilisation strategies for normal and malignant cells. Pathology 2011;43:547-65. [PMID: 21921732 DOI: 10.1097/PAT.0b013e32834a9eb8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
190 Martelli AM, Tabellini G, Ricci F, Evangelisti C, Chiarini F, Bortul R, Mccubrey JA, Manzoli FA. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy. Advances in Biological Regulation 2012;52:214-27. [DOI: 10.1016/j.advenzreg.2011.09.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
191 Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R, Ghobrial IM, Griffin JD. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 2012;26:985-90. [PMID: 22182920 DOI: 10.1038/leu.2011.360] [Cited by in Crossref: 86] [Cited by in F6Publishing: 90] [Article Influence: 7.2] [Reference Citation Analysis]
192 O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 2012;119:1717-25. [PMID: 22186993 DOI: 10.1182/blood-2011-04-347518] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
193 Choi WT, Duggineni S, Xu Y, Huang Z, An J. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). J Med Chem 2012;55:977-94. [PMID: 22085380 DOI: 10.1021/jm200568c] [Cited by in Crossref: 89] [Cited by in F6Publishing: 91] [Article Influence: 7.4] [Reference Citation Analysis]
194 Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 2012;26:788-94. [PMID: 22033489 DOI: 10.1038/leu.2011.285] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
195 Schroeder MA, DiPersio JF. Mobilization of hematopoietic stem and leukemia cells. J Leukoc Biol. 2012;91:47-57. [PMID: 22028335 DOI: 10.1189/jlb.0210085] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
196 Zhang X, Liu Y, Si YJ, Chen XH, Li ZJ, Gao L, Gao L, Zhang C. Effect of Cx43 gene-modified leukemic bone marrow stromal cells on the regulation of Jurkat cell line in vitro. Leuk Res. 2012;36:198-204. [PMID: 22030334 DOI: 10.1016/j.leukres.2011.10.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
197 Blau O, Baldus CD, Hofmann WK, Thiel G, Nolte F, Burmeister T, Türkmen S, Benlasfer O, Schümann E, Sindram A, Molkentin M, Mundlos S, Keilholz U, Thiel E, Blau IW. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011;118:5583-92. [PMID: 21948175 DOI: 10.1182/blood-2011-03-343467] [Cited by in Crossref: 122] [Cited by in F6Publishing: 133] [Article Influence: 10.2] [Reference Citation Analysis]
198 Wong RS. Mesenchymal stem cells: angels or demons? J Biomed Biotechnol. 2011;2011:459510. [PMID: 21822372 DOI: 10.1155/2011/459510] [Cited by in Crossref: 65] [Cited by in F6Publishing: 89] [Article Influence: 5.4] [Reference Citation Analysis]
199 Nwabo Kamdje AH, Mosna F, Bifari F, Lisi V, Bassi G, Malpeli G, Ricciardi M, Perbellini O, Scupoli MT, Pizzolo G. Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood. 2011;118:380-389. [PMID: 21602525 DOI: 10.1182/blood-2010-12-326694] [Cited by in Crossref: 85] [Cited by in F6Publishing: 94] [Article Influence: 7.1] [Reference Citation Analysis]
200 Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F 3rd. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 2011;29:11-19. [PMID: 21280155 DOI: 10.1002/stem.559] [Cited by in Crossref: 391] [Cited by in F6Publishing: 409] [Article Influence: 32.6] [Reference Citation Analysis]
201 Hu KX, Wang MH, Fan C, Wang L, Guo M, Ai HS. CM-DiI labeled mesenchymal stem cells homed to thymus inducing immune recovery of mice after haploidentical bone marrow transplantation. Int Immunopharmacol 2011;11:1265-70. [PMID: 21530684 DOI: 10.1016/j.intimp.2011.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
202 Marigo I, Dazzi F. The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol 2011;33:593-602. [DOI: 10.1007/s00281-011-0267-7] [Cited by in Crossref: 130] [Cited by in F6Publishing: 115] [Article Influence: 10.8] [Reference Citation Analysis]
203 Huang TT, Liu FG, Wei CF, Lu CC, Chen CC, Lin HC, Ojcius DM, Lai HC. Activation of multiple apoptotic pathways in human nasopharyngeal carcinoma cells by the prenylated isoflavone, osajin. PLoS One 2011;6:e18308. [PMID: 21532751 DOI: 10.1371/journal.pone.0018308] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
204 Sanchez CG, Penfornis P, Oskowitz AZ, Boonjindasup AG, Cai DZ, Dhule SS, Rowan BG, Kelekar A, Krause DS, Pochampally RR. Activation of autophagy in mesenchymal stem cells provides tumor stromal support. Carcinogenesis 2011;32:964-72. [PMID: 21317300 DOI: 10.1093/carcin/bgr029] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 6.6] [Reference Citation Analysis]
205 Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011;29:591-9. [PMID: 21220598 DOI: 10.1200/JCO.2010.31.0904] [Cited by in Crossref: 295] [Cited by in F6Publishing: 317] [Article Influence: 24.6] [Reference Citation Analysis]
206 Tolar J, Villeneuve P, Keating A. Mesenchymal stromal cells for graft-versus-host disease. Hum Gene Ther 2011;22:257-62. [PMID: 21288086 DOI: 10.1089/hum.2011.1104] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
207 Huang TT, Lin HC, Chen CC, Lu CC, Wei CF, Wu TS, Liu FG, Lai HC. Resveratrol induces apoptosis of human nasopharyngeal carcinoma cells via activation of multiple apoptotic pathways. J Cell Physiol. 2011;226:720-728. [PMID: 20717957 DOI: 10.1002/jcp.22391] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
208 Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O, Amedei A, Veltroni M, D'amico M, Basso G, Becchetti A, Campana D, Arcangeli A. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 2011;117:902-14. [DOI: 10.1182/blood-2010-01-262691] [Cited by in Crossref: 99] [Cited by in F6Publishing: 102] [Article Influence: 8.3] [Reference Citation Analysis]
209 Wang M, Medeiros BC, Erba HP, DeAngelo DJ, Giles FJ, Swords RT. Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opin Ther Targets 2011;15:253-64. [PMID: 21219242 DOI: 10.1517/14728222.2011.550877] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
210 Brune JC, Tormin A, Johansson MC, Rissler P, Brosjö O, Löfvenberg R, von Steyern FV, Mertens F, Rydholm A, Scheding S. Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts. Int J Cancer 2011;129:319-30. [DOI: 10.1002/ijc.25697] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
211 Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010;116:5089-102. [PMID: 20705759 DOI: 10.1182/blood-2010-04-261867] [Cited by in Crossref: 272] [Cited by in F6Publishing: 289] [Article Influence: 20.9] [Reference Citation Analysis]
212 Rao R, Nalluri S, Fiskus W, Balusu R, Joshi A, Mudunuru U, Buckley KM, Robbins K, Ustun C, Reuther GW, Bhalla KN. Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cells. Mol Cancer Ther 2010;9:2232-42. [PMID: 20663926 DOI: 10.1158/1535-7163.MCT-10-0336] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
213 Tavor S, Petit I. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? Semin Cancer Biol 2010;20:178-85. [PMID: 20637871 DOI: 10.1016/j.semcancer.2010.07.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
214 Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene 2010;29:5120-34. [DOI: 10.1038/onc.2010.273] [Cited by in Crossref: 73] [Cited by in F6Publishing: 79] [Article Influence: 5.6] [Reference Citation Analysis]
215 Li X, Marcondes AM, Gooley TA, Deeg HJ. The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood 2010;116:2304-14. [PMID: 20562331 DOI: 10.1182/blood-2009-09-242313] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
216 Kremser A, Dressig J, Grabrucker C, Liepert A, Kroell T, Scholl N, Schmid C, Tischer J, Kufner S, Salih H, Kolb HJ, Schmetzer H. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother 2010;33:185-99. [PMID: 20139775 DOI: 10.1097/CJI.0b013e3181b8f4ce] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
217 Wang X, Zhang Z, Yao C. Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells. Leuk Res 2010;34:1325-9. [PMID: 20627293 DOI: 10.1016/j.leukres.2010.05.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
218 Zhi L, Wang M, Rao Q, Yu F, Mi Y, Wang J. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance. Cancer Lett. 2010;296:65-73. [PMID: 20444543 DOI: 10.1016/j.canlet.2010.03.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
219 Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller J, Fruehauf S. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. Leuk Lymphoma 2009;50:1676-86. [PMID: 19657955 DOI: 10.1080/10428190903150847] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
220 Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010;115:3796-800. [PMID: 20203261 DOI: 10.1182/blood-2009-11-254862] [Cited by in Crossref: 193] [Cited by in F6Publishing: 204] [Article Influence: 14.8] [Reference Citation Analysis]
221 Becchetti A, Pillozzi S, Morini R, Nesti E, Arcangeli A. New insights into the regulation of ion channels by integrins. Int Rev Cell Mol Biol 2010;279:135-90. [PMID: 20797679 DOI: 10.1016/S1937-6448(10)79005-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
222 Smith BD, Karp JE. What are the endpoints of therapy for acute leukemias? Old definitions and new challenges. Clin Lymphoma Myeloma 2009;9 Suppl 3:S296-301. [PMID: 19778856 DOI: 10.3816/CLM.2009.s.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
223 Marcondes AM, Li X, Gooley TA, Milless B, Deeg HJ. Identification of DJ-1/PARK-7 as a determinant of stroma-dependent and TNF-alpha-induced apoptosis in MDS using mass spectrometry and phosphopeptide analysis. Blood 2010;115:1993-2002. [PMID: 20061558 DOI: 10.1182/blood-2009-08-236992] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
224 Calandra G, Bridger G, Fricker S. CXCR4 in clinical hematology. Curr Top Microbiol Immunol 2010;341:173-91. [PMID: 20397073 DOI: 10.1007/82_2010_26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 23] [Article Influence: 0.7] [Reference Citation Analysis]
225 Konoplev S, Bueso-ramos C. Acute Myeloid Leukemias with Normal Cytogenetics. Molecular Pathology Library 2010. [DOI: 10.1007/978-1-4419-5698-9_35] [Reference Citation Analysis]
226 Taub JW, Ge Y, Ravindranath Y. Down Syndrome and Acute Myeloid Leukemia: An Unique Genetic Sensitivity to Chemotherapy. Molecularly Targeted Therapy for Childhood Cancer 2010. [DOI: 10.1007/978-0-387-69062-9_6] [Reference Citation Analysis]
227 Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, Xia Z, Zhang Z, Aplan PD, Aster JC, Smith CD. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010;115:824-833. [PMID: 19965690 DOI: 10.1182/blood-2009-07-233445] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 6.5] [Reference Citation Analysis]
228 Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood. 2010;115:306-314. [PMID: 19897582 DOI: 10.1182/blood-2009-03-212563] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
229 Wei Z, Chen N, Guo H, Wang X, Xu F, Ren Q, Lu S, Liu B, Zhang L, Zhao H. Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells. J Exp Clin Cancer Res 2009;28:141. [PMID: 19883517 DOI: 10.1186/1756-9966-28-141] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
230 Foss B, Tronstad KJ, Bruserud Ø. Connexin-based signaling in acute myelogenous leukemia (AML). Biochim Biophys Acta 2010;1798:1-8. [PMID: 19883623 DOI: 10.1016/j.bbamem.2009.10.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
231 Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009;23:2233-41. [PMID: 19727127 DOI: 10.1038/leu.2009.175] [Cited by in Crossref: 189] [Cited by in F6Publishing: 201] [Article Influence: 13.5] [Reference Citation Analysis]
232 Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 2009;8:2509-16. [PMID: 19723894 DOI: 10.1158/1535-7163.MCT-09-0386] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
233 Westhoff MA, Fulda S. Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat. 2009;12:127-136. [PMID: 19726220 DOI: 10.1016/j.drup.2009.08.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
234 Lancet JE, Karp JE. Novel postremission strategies in adults with acute myeloid leukemia. Curr Opin Hematol 2009;16:105-11. [PMID: 19468272 DOI: 10.1097/MOH.0b013e3283257b04] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
235 Ding J, Han F, Shi Y. Single-prolonged stress induces apoptosis in the amygdala in a rat model of post-traumatic stress disorder. J Psychiatr Res 2010;44:48-55. [PMID: 19586638 DOI: 10.1016/j.jpsychires.2009.06.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
236 Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009;113:6215-24. [PMID: 18955566 DOI: 10.1182/blood-2008-05-158311] [Cited by in Crossref: 390] [Cited by in F6Publishing: 412] [Article Influence: 27.9] [Reference Citation Analysis]
237 Burger JA. CXCR4 in acute myelogenous leukemia (AML): when too much attraction is bad for you. Leuk Res 2009;33:747-8. [PMID: 19091405 DOI: 10.1016/j.leukres.2008.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
238 Mayani H, Flores-figueroa E, Chávez-gonzález A. In vitro biology of human myeloid leukemia. Leukemia Research 2009;33:624-37. [DOI: 10.1016/j.leukres.2008.11.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
239 Muranyi AL, Dedhar S, Hogge DE. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. Exp Hematol 2009;37:450-60. [PMID: 19302919 DOI: 10.1016/j.exphem.2009.01.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
240 Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 2009;69:2163-6. [PMID: 19258498 DOI: 10.1158/0008-5472.CAN-08-3722] [Cited by in Crossref: 212] [Cited by in F6Publishing: 228] [Article Influence: 15.1] [Reference Citation Analysis]
241 Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 2008;49:2246-55. [PMID: 19052971 DOI: 10.1080/10428190802510349] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
242 Zhu Y, Sun Z, Han Q, Liao L, Wang J, Bian C, Li J, Yan X, Liu Y, Shao C. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia. 2009;23:925-933. [PMID: 19148141 DOI: 10.1038/leu.2008.384] [Cited by in Crossref: 219] [Cited by in F6Publishing: 239] [Article Influence: 15.6] [Reference Citation Analysis]
243 Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 2009;12:103-13. [PMID: 19632887 DOI: 10.1016/j.drup.2009.06.001] [Cited by in Crossref: 125] [Cited by in F6Publishing: 136] [Article Influence: 8.9] [Reference Citation Analysis]
244 Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43-52. [PMID: 18987663 DOI: 10.1038/leu.2008.299] [Cited by in Crossref: 340] [Cited by in F6Publishing: 362] [Article Influence: 24.3] [Reference Citation Analysis]
245 Tavernier-Tardy E, Cornillon J, Campos L, Flandrin P, Duval A, Nadal N, Guyotat D. Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res 2009;33:764-8. [PMID: 19042019 DOI: 10.1016/j.leukres.2008.10.014] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
246 Silveira NJ, Varuzza L, Machado-Lima A, Lauretto MS, Pinheiro DG, Rodrigues RV, Severino P, Nobrega FG, Silva WA Jr, de B Pereira CA, Tajara EH; Head and Neck Genome Project GENCAPO. Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries. BMC Med Genomics 2008;1:56. [PMID: 19014460 DOI: 10.1186/1755-8794-1-56] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
247 Mhyre AJ, Marcondes AM, Spaulding EY, Deeg HJ. Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD. Blood 2009;113:649-58. [PMID: 18945969 DOI: 10.1182/blood-2008-04-152686] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
248 Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. British Journal of Haematology 2008;142:695-708. [DOI: 10.1111/j.1365-2141.2008.07245.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 4.3] [Reference Citation Analysis]
249 Xu G, Zhang Y, Zhang L, Ren G, Shi Y. Bone marrow stromal cells induce apoptosis of lymphoma cells in the presence of IFNgamma and TNF by producing nitric oxide. Biochem Biophys Res Commun 2008;375:666-70. [PMID: 18755151 DOI: 10.1016/j.bbrc.2008.08.077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
250 Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M. The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 2008;68:5198-205. [PMID: 18593920 DOI: 10.1158/0008-5472.CAN-08-0555] [Cited by in Crossref: 123] [Cited by in F6Publishing: 128] [Article Influence: 8.2] [Reference Citation Analysis]
251 Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, Adamia S, Stone R, Galinsky I, Kung AL, Griffin JD. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 2008;7:1121-9. [PMID: 18445657 DOI: 10.1158/1535-7163.MCT-07-2331] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.6] [Reference Citation Analysis]
252 Moshaver B, van der Pol MA, Westra AH, Ossenkoppele GJ, Zweegman S, Schuurhuis GJ. Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival. Leuk Lymphoma 2008;49:134-48. [PMID: 17926185 DOI: 10.1080/10428190701593636] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
253 Liang R, Huang G, Wang Z, Chen X, Bai Q, Zhang Y, Dong B, Wang W. Effects of human bone marrow stromal cell line (HFCL) on the proliferation, differentiation and apoptosis of acute myeloid leukemia cell lines U937, HL-60 and HL-60/VCR. Int J Hematol 2008;87:152-66. [DOI: 10.1007/s12185-008-0030-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
254 Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci U S A. 2008;105:2865-2870. [PMID: 18287021 DOI: 10.1073/pnas.0712391105] [Cited by in Crossref: 108] [Cited by in F6Publishing: 112] [Article Influence: 7.2] [Reference Citation Analysis]
255 Zhou HB, Chen JM, Cai JT, Du Q, Wu CN. Anticancer activity of genistein on implanted tumor of human SG7901 cells in nude mice. World J Gastroenterol 2008; 14(4): 627-631 [PMID: 18203299 DOI: 10.3748/wjg.14.627] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
256 Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007;35:1739-46. [PMID: 17976524 DOI: 10.1016/j.exphem.2007.09.007] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 5.7] [Reference Citation Analysis]
257 Campana D, Pui C. Childhood Leukemia. Abeloff's Clinical Oncology 2008. [DOI: 10.1016/b978-0-443-06694-8.50105-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
258 Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008;111:2300-9. [PMID: 18056841 DOI: 10.1182/blood-2007-06-098012] [Cited by in Crossref: 164] [Cited by in F6Publishing: 172] [Article Influence: 10.3] [Reference Citation Analysis]
259 Ong V, Liem NL, Schmid MA, Verrills NM, Papa RA, Marshall GM, Mackenzie KL, Kavallaris M, Lock RB. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts. J Pharmacol Exp Ther 2008;324:434-42. [PMID: 17986648 DOI: 10.1124/jpet.107.128926] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
260 Wierzbowska A, Robak T, Krawczyńska A, Pluta A, Wrzesień-kuś A, Cebula B, Robak E, Smolewski P. Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients. Ann Hematol 2008;87:97-106. [DOI: 10.1007/s00277-007-0372-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
261 Wang X, Wang C, Yan S, Gao Y. XIAP is upregulated in HL-60 cells cocultured with stromal cells by direct cell contact. Leukemia Research 2007;31:1125-9. [DOI: 10.1016/j.leukres.2006.09.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
262 Han KQ, Huang G, Gu W, Su YH, Huang XQ, Ling CQ. Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenterol 2007; 13(24): 3374-3379 [PMID: 17659679 DOI: 10.3748/wjg.v13.i24.3374] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 88] [Article Influence: 5.3] [Reference Citation Analysis]
263 Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 2007;21:1521-31. [PMID: 17476277 DOI: 10.1038/sj.leu.2404723] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 4.1] [Reference Citation Analysis]
264 Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, Fricker S, Fujii N, Bradstock KF, Bendall LJ. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 2007;21:1249-57. [PMID: 17410186 DOI: 10.1038/sj.leu.2404684] [Cited by in Crossref: 105] [Cited by in F6Publishing: 109] [Article Influence: 6.6] [Reference Citation Analysis]
265 Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips G, Abboud CN. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res. 2007;31:1553-1563. [PMID: 17403536 DOI: 10.1016/j.leukres.2007.02.017] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 3.3] [Reference Citation Analysis]
266 Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117:1049-57. [PMID: 17380207 DOI: 10.1172/JCI30235] [Cited by in Crossref: 250] [Cited by in F6Publishing: 258] [Article Influence: 15.6] [Reference Citation Analysis]
267 Mesa RA, Kaufmann SH. Altered Apoptosis in AML. Acute Myelogenous Leukemia 2007. [DOI: 10.1007/978-1-59745-322-6_6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
268 Karp JE. Leukemia does not live by 1 lesion alone. Blood 2006;108:2133-4. [DOI: 10.1182/blood-2006-07-034660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
269 Lee C, Lin Y, Huang M, Lin C, Liu C, Chow J, Liu HE. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo. Leuk Lymphoma 2006;47:521-9. [PMID: 16396776 DOI: 10.1080/10428190500305851] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
270 Spoo AC, Lübbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109:786-791. [PMID: 16888090 DOI: 10.1182/blood-2006-05-024844] [Cited by in Crossref: 236] [Cited by in F6Publishing: 251] [Article Influence: 13.9] [Reference Citation Analysis]
271 Liesveld JL, Rosell KE, Lu C, Bechelli J, Phillips G, Lancet JE, Abboud CN. Acute myelogenous leukemia--microenvironment interactions: Role of endothelial cells and proteasome inhibition. Hematology. 2005;10:483-494. [PMID: 16321813 DOI: 10.1080/10245330500233452] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
272 Lin Y, Zhang G, Leng Z, Lu Z, Bu L, Gao S, Yang S. Study on the bone marrow mesenchymal stem cells induced drug resistance in the U937 cells and its mechanism: . Chinese Medical Journal 2006;119:905-10. [DOI: 10.1097/00029330-200606010-00005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
273 Vial J, Tabrizi R, Pigneux A, Lacombe F, Praloran V, Belloc F. Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes. Cytometry 2006;70B:115-23. [DOI: 10.1002/cyto.b.20105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
274 Dick JE, Lapidot T. Biology of Normal and Acute Myeloid Leukemia Stem Cells. International Journal of Hematology 2005;82:389-96. [DOI: 10.1532/ijh97.05144] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 4.4] [Reference Citation Analysis]
275 Oliver L, Vallette FM. The role of caspases in cell death and differentiation. Drug Resist Updat. 2005;8:163-170. [PMID: 15946892 DOI: 10.1016/j.drup.2005.05.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 2.9] [Reference Citation Analysis]
276 Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, Ravindranath Y, Matherly LH, Taub JW. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 2006;107:1570-81. [PMID: 16249385 DOI: 10.1182/blood-2005-06-2219] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 4.4] [Reference Citation Analysis]
277 Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005;11:389-398. [PMID: 15846293 DOI: 10.1016/j.bbmt.2005.02.001] [Cited by in Crossref: 626] [Cited by in F6Publishing: 651] [Article Influence: 34.8] [Reference Citation Analysis]
278 Bertrand FE, Spengemen JD, Shelton JG, McCubrey JA. Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia 2005;19:98-102. [PMID: 15496972 DOI: 10.1038/sj.leu.2403560] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
279 Zhou HB, Yan Y, Cai JT, Du Q, Chen JM. Genistein induces apoptosis in human primary gastric carcinoma cells. Shijie Huaren Xiaohua Zazhi 2005; 13(4): 504-507 [DOI: 10.11569/wcjd.v13.i4.504] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
280 Zhou HB, Chen JJ, Wang WX, Cai JT, Du Q. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol 2005; 11(2): 280-284 [PMID: 15633232 DOI: 10.3748/wjg.v11.i2.280] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 74] [Article Influence: 3.8] [Reference Citation Analysis]
281 D'Alessio M, Cerella C, Amici C, Pesce C, Coppola S, Fanelli C, De Nicola M, Cristofanon S, Clavarino G, Bergamaschi A, Magrini A, Gualandi G, Ghibelli L. Glutathione depletion up-regulates Bcl-2 in BSO-resistant cells. FASEB J 2004;18:1609-11. [PMID: 15289449 DOI: 10.1096/fj.04-1813fje] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
282 Zhou HB, Chen JJ, Wang WX, Cai JT, Du Q. Apoptosis of human primary gastric carcinoma cells induced by genistein. World J Gastroenterol 2004; 10(12): 1822-1825 [PMID: 15188515 DOI: 10.3748/wjg.v10.i12.1822] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
283 Liem NLM, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD, Mackenzie KL, Lock RB. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004;103:3905-14. [DOI: 10.1182/blood-2003-08-2911] [Cited by in Crossref: 190] [Cited by in F6Publishing: 193] [Article Influence: 10.0] [Reference Citation Analysis]
284 Li ZM, Liu ZC, Guan ZZ, Zhu XF, Zhou JM, Xie BF, Feng GK, Zhu ZY, Jiang WQ. Inhibition of DNA primase and induction of apoptosis by 3,3’-diethyl-9-methylthia-carbocyanine iodide in hepatocellular carcinoma BEL-7402 cells. World J Gastroenterol 2004; 10(4): 514-520 [PMID: 14966908 DOI: 10.3748/wjg.v10.i4.514] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
285 van Stijn A, Kok A, van Stalborch MA, van der Pol MA, Feller N, Westra AH, Ossenkoppele GJ, Schuurhuis GJ. Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile. Leukemia 2004;18:875-7. [DOI: 10.1038/sj.leu.2403299] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
286 Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003;22:9063-74. [DOI: 10.1038/sj.onc.1207229] [Cited by in Crossref: 146] [Cited by in F6Publishing: 152] [Article Influence: 7.3] [Reference Citation Analysis]
287 Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, McQueen T, Tsao T, Zhao S, Pierce S, Igari J, Estey EH, Andreeff M. PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 2004;103:1815-22. [PMID: 14630813 DOI: 10.1182/blood-2003-03-0802] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 3.6] [Reference Citation Analysis]
288 Carter BZ, Milella M, Tsao T, Mcqueen T, Schober WD, Hu W, Dean NM, Steelman L, Mccubrey JA, Andreeff M. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 2003;17:2081-9. [DOI: 10.1038/sj.leu.2403113] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 4.3] [Reference Citation Analysis]
289 Paraguassú-braga FH, Borojevic R, Bouzas LF, Barcinski MA, Bonomo A. Bone marrow stroma inhibits proliferation and apoptosis in leukemic cells through gap junction-mediated cell communication. Cell Death Differ 2003;10:1101-8. [DOI: 10.1038/sj.cdd.4401279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 2.5] [Reference Citation Analysis]
290 Zhou HB, Yan Y, Sun YN, Zhu JR. Resveratrol induces apoptosis in human esophageal carcinoma cells. World J Gastroenterol 2003; 9(3): 408-411 [PMID: 12632486 DOI: 10.3748/wjg.v9.i3.408] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 55] [Article Influence: 2.6] [Reference Citation Analysis]
291 Zhou HB, Zhu JR. Paclitaxel induces apoptosis in human gastric carcinoma cells. World J Gastroenterol 2003; 9(3): 442-445 [PMID: 12632493 DOI: 10.3748/wjg.v9.i3.442] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
292 [DOI: 10.1101/806992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]